Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Torcetrapib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP known ✓ | P11597 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Torcetrapib SCHEMBL10041443 | 1.00 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL49081 | 1.00 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL29403162 | 1.00 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL6277910 | 1.00 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL7169875 | 1.00 | CETP (1.00) | CETP | |
| SCHEMBL18027496 | 0.97 | CETP (0.94) | CETP | |
| SCHEMBL12756768 | 0.96 | CETP (0.92) | CETP | |
| Torcetrapib SCHEMBL3185801 | 0.96 | CETP (0.92) | CETP | |
| Torcetrapib SCHEMBL3187101 | 0.96 | CETP (0.92) | CETP | |
| Torcetrapib SCHEMBL3187095 | 0.96 | CETP (0.92) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893178-A1 | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS | Pfizer Products Incorporated (US) | 2008-03-05 | — | — | EP | claimed |
| WO-2007107843-A1 | METHODS OF TREATMENT WITH CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-09-27 | — | — | WO | claimed |
| WO-2006129167-A1 | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-12-07 | — | — | WO | claimed |
| EP-1633747-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS PPAR-A ACTIVATORS | Pfizer Products Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| WO-2006021401-A2 | BICYLONONENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-02 | — | — | WO | claimed |
| US-6906082-B2 | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | PFIZER INC. (US) | 2005-06-14 | — | — | US | claimed |
| WO-2004103997-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS PPAR-α ACTIVATORS | PFIZER PRODUCTS INC. (US) | 2004-12-02 | — | — | WO | claimed |
| US-6586448-B1 | Cholesteryl ester transfer protein inhibitors used as antilipemic agents for prophylaxis of cardiovascular disorders | PFIZER INC. | 2003-07-01 | — | — | US | claimed |
| US-11116728-B2 | Multiparticulates of spray-coated drug and polymer on a meltable core | BEND RESEARCH, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| EP-1469833-B1 | METHOD FOR MAKING HOMOGENEOUS SPRAY-DRIED SOLID AMORPHOUS DRUG DISPERSIONS UTILIZING MODIFIED SPRAY-DRYING APPARATUS | BEND RES INC (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-3648747-A1 | GASTRORETENTIVE DOSAGE FORMS FOR SUSTAINED DRUG DELIVERY | Kashiv Biosciences, LLC (US) | 2020-05-13 | — | — | EP | disclosed |
| EP-3628004-A1 | SELF-REGULATING OSMOTIC GASTRORETENTIVE DRUG DELIVERY SYSTEMS | Kashiv Biosciences, LLC (US) | 2020-04-01 | — | — | EP | disclosed |
| US-20190307702-A1 | MULTIPARTICULATES OF SPRAY-COATED DRUG AND POLYMER ON A MELTABLE CORE | BEND RESEARCH, INC. (US) | 2019-10-10 | — | — | US | disclosed |
| WO-2018232413-A1 | GASTRORETENTIVE DOSAGE FORMS FOR SUSTAINED DRUG DELIVERY | KASHIV PHARMA LLC (US) | 2018-12-20 | — | — | WO | disclosed |
| EP-1246804-A1 | 4-CARBOXYAMINO-2-ETHYL-1,2,3,4-TETRAHYDROQUINOLINE CRYSTAL AS CETP INHIBITOR | Pfizer Products Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
| US-20020035125-A1 | Therapeutic combination | SHEAR CHARLES L (US) | 2002-03-21 | — | — | US | disclosed |
| WO-2002013797-A2 | THERAPEUTIC COMBINATION OF A CETP INHIBITOR AND ATORVASTATIN | PFIZER PRODUCTS INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| EP-1125929-A1 | Method for making (-)-(2R,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonylamino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2001040190-A1 | 4-CARBOXYAMINO-2-ETHYL-1,2,3,4-TETRAHYDROQUINOLINE CRYSTAL AS CETP INHIBITOR | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| US-6197786-B1 | ANTICHOLESTEROL AGENTS | PFIZER INC | 2001-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035125-A1 | Therapeutic combination | CETP, HMGCR, PCSK9 | CETP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.